title: Sister chromatid exchange studies for monitoring DNA damage in lymphocytes of malignant lymphoma patients under cytostatic therapy.
abstract: Sister chromatid exchange (SCE) frequencies were studied in lymphocytes from 45 patients with malignant lymphoma. Fifteen patients were untreated when studied. The mean SCE frequency for these patients was 8.70 +/- 0.99 per mitosis. The mean score for 35 controls was 4.37 +/- 1.19. SCE mean scores were significantly higher in the untreated patients than in the controls (p < 0.001). Nine patients were treated with radiotherapy alone. The mean SCE frequency (6.80 +/- 0.87) they demonstrated was significantly lower (p < 0.01) than that found in untreated patients. Twelve patients received cyclophosphamide 1 month before the study was started. They demonstrated a mean SCE frequency (12.00 +/- 1.31) significantly higher (p < 0.05) than that found in patients who had received regimens that did not contain cyclophosphamide (9.72 +/- 1.32). From these findings we suggest that untreated patients with malignant lymphoma have elevated SCE frequencies, which may be further increased by chemotherapeutic agents.
authors.affiliation: Department of Toxicology, Gazi University, Faculty of Pharmacy, Ankara, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Sardaş
authors.forename: F
authors.initials: F
authors.lastname: Erdoğan
authors.forename: O S
authors.initials: OS
authors.lastname: Sardaş
authors.forename: M
authors.initials: M
authors.lastname: Cengel
authors.forename: A E
authors.initials: AE
authors.lastname: Karakaya
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000627:therapeutic use; D004249:DNA Damage; D004317:Doxorubicin / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008214:Lymphocytes / Q000187:drug effects* / Q000502:physiology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000235:genetics* / Q000532:radiotherapy; D012854:Sister Chromatid Exchange
chemical_list: D000970:Antineoplastic Agents; D001761:Bleomycin; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide